55 related articles for article (PubMed ID: 2233701)
1. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.
Murphy CS; Langan-Fahey SM; McCague R; Jordan VC
Mol Pharmacol; 1990 Nov; 38(5):737-43. PubMed ID: 2233701
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of bioactive tamoxifen-conjugated polymers.
Rickert EL; Trebley JP; Peterson AC; Morrell MM; Weatherman RV
Biomacromolecules; 2007 Nov; 8(11):3608-12. PubMed ID: 17929966
[TBL] [Abstract][Full Text] [Related]
3. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of indole-modified tamoxifen relatives as potent anticancer agents.
Ertugrul B; Aytatli A; Karatas OF; Saracoglu N
RSC Med Chem; 2023 Jul; 14(7):1362-1376. PubMed ID: 37484572
[TBL] [Abstract][Full Text] [Related]
5. Estrogen for the Treatment and Prevention of Breast Cancer: A Tale of 2 Karnofsky Lectures.
Abderrahman B; Jordan VC
Cancer J; 2022 May-Jun 01; 28(3):163-168. PubMed ID: 35594462
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors.
Koubek EJ; Ralya AT; Larson TR; McGovern RM; Buhrow SA; Covey JM; Adjei AA; Takebe N; Ames MM; Goetz MP; Reid JM
J Clin Pharmacol; 2022 Sep; 62(9):1121-1131. PubMed ID: 35358345
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of NR ligand polypharmacology by a multiplex reporter NR assay.
Medvedev A; Moeser M; Medvedeva L; Martsen E; Granick A; Raines L; Gorman K; Lin B; Zeng M; Houck KA; Makarov SS
Sci Rep; 2022 Feb; 12(1):3115. PubMed ID: 35210493
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.
Takebe N; Coyne GO; Kummar S; Collins J; Reid JM; Piekarz R; Moore N; Juwara L; Johnson BC; Bishop R; Lin FI; Mena E; Choyke PL; Lindenberg ML; Rubinstein LV; Bonilla CM; Goetz MP; Ames MM; McGovern RM; Streicher H; Covey JM; Doroshow JH; Chen AP
Oncotarget; 2021 Feb; 12(4):268-277. PubMed ID: 33659039
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
Abderrahman B; Maximov PY; Curpan RF; Hanspal JS; Fan P; Xiong R; Tonetti DA; Thatcher GRJ; Jordan VC
Mol Pharmacol; 2020 Oct; 98(4):364-381. PubMed ID: 32788222
[TBL] [Abstract][Full Text] [Related]
10. The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture.
Jordan VC
Ann Surg Oncol; 2019 Jul; 26(7):1981-1990. PubMed ID: 30911948
[TBL] [Abstract][Full Text] [Related]
11. The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.
Johänning J; Kröner P; Thomas M; Zanger UM; Nörenberg A; Eichelbaum M; Schwab M; Brauch H; Schroth W; Mürdter TE
Arch Toxicol; 2018 Mar; 92(3):1099-1112. PubMed ID: 29285606
[TBL] [Abstract][Full Text] [Related]
12. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.
Fan P; Maximov PY; Curpan RF; Abderrahman B; Jordan VC
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):245-63. PubMed ID: 26052034
[TBL] [Abstract][Full Text] [Related]
13. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
14. Live imaging of innate immune and preneoplastic cell interactions using an inducible Gal4/UAS expression system in larval zebrafish skin.
Ramezani T; Laux DW; Bravo IR; Tada M; Feng Y
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741625
[TBL] [Abstract][Full Text] [Related]
15. Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
Maximov PY; Fernandes DJ; McDaniel RE; Myers CB; Curpan RF; Jordan VC
J Med Chem; 2014 Jun; 57(11):4569-83. PubMed ID: 24805199
[TBL] [Abstract][Full Text] [Related]
16. Ribonuclease-Activated Cancer Prodrug.
Ellis GA; McGrath NA; Palte MJ; Raines RT
ACS Med Chem Lett; 2012 Feb; 3(4):268-272. PubMed ID: 22611478
[TBL] [Abstract][Full Text] [Related]
17. Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
Maximov PY; Myers CB; Curpan RF; Lewis-Wambi JS; Jordan VC
J Med Chem; 2010 Apr; 53(8):3273-83. PubMed ID: 20334368
[TBL] [Abstract][Full Text] [Related]
18. Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity.
Zhou HB; Carlson KE; Stossi F; Katzenellenbogen BS; Katzenellenbogen JA
Bioorg Med Chem Lett; 2009 Jan; 19(1):108-10. PubMed ID: 19014882
[TBL] [Abstract][Full Text] [Related]
19. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.
Jordan VC
Steroids; 2007 Nov; 72(13):829-42. PubMed ID: 17765940
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
